MedWatch

Lundbeck launches alcohol pill in UK

Alcohol dependant Britons will be given access to Lundbeck’s new alcohol pill Selincro. It triggers a milestone payment for partner Biotie.

Foto: Colourbox, genrebillede

The new alcohol pill Selincro, which is developed and being marketed by Lundbeck and partner Biotie, has made its entry into the British market. The development triggers a milestone payment of 2 million Euros to Biotie.

“Biotie will potentially contribute to Lundbeck towards any required post approval commitment studies. These contributions are not expected to be significant in 2013,” Biotie writes in a press release.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier